[go: up one dir, main page]

WO2018096525A3 - Composés hétéroaryle et utilisations associées - Google Patents

Composés hétéroaryle et utilisations associées Download PDF

Info

Publication number
WO2018096525A3
WO2018096525A3 PCT/IB2018/052089 IB2018052089W WO2018096525A3 WO 2018096525 A3 WO2018096525 A3 WO 2018096525A3 IB 2018052089 W IB2018052089 W IB 2018052089W WO 2018096525 A3 WO2018096525 A3 WO 2018096525A3
Authority
WO
WIPO (PCT)
Prior art keywords
heteroaryl compounds
compounds
methods
pharmaceutically acceptable
heteroaryl
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/IB2018/052089
Other languages
English (en)
Other versions
WO2018096525A2 (fr
Inventor
Peter Anthony CICALA
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Celgene Corp
Original Assignee
Celgene Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Celgene Corp filed Critical Celgene Corp
Priority to PCT/IB2018/052089 priority Critical patent/WO2018096525A2/fr
Publication of WO2018096525A2 publication Critical patent/WO2018096525A2/fr
Publication of WO2018096525A3 publication Critical patent/WO2018096525A3/fr
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

La présente invention concerne des composés, des compositions pharmaceutiquement acceptables de ces composés, et des méthodes d'utilisation correspondantes.
PCT/IB2018/052089 2018-03-27 2018-03-27 Composés hétéroaryle et utilisations associées Ceased WO2018096525A2 (fr)

Priority Applications (1)

Application Number Priority Date Filing Date Title
PCT/IB2018/052089 WO2018096525A2 (fr) 2018-03-27 2018-03-27 Composés hétéroaryle et utilisations associées

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
PCT/IB2018/052089 WO2018096525A2 (fr) 2018-03-27 2018-03-27 Composés hétéroaryle et utilisations associées

Publications (2)

Publication Number Publication Date
WO2018096525A2 WO2018096525A2 (fr) 2018-05-31
WO2018096525A3 true WO2018096525A3 (fr) 2018-09-27

Family

ID=62195457

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/IB2018/052089 Ceased WO2018096525A2 (fr) 2018-03-27 2018-03-27 Composés hétéroaryle et utilisations associées

Country Status (1)

Country Link
WO (1) WO2018096525A2 (fr)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3578555B1 (fr) * 2018-01-16 2022-09-21 Shenzhen TargetRx, Inc. Composé de diphénylaminopyrimidine inhibant l'activité kinase
CA3156007A1 (fr) 2019-09-27 2021-04-01 Disc Medicine, Inc. Procedes de traitement de la myelofibrose et d'affections associees
JP2023528223A (ja) 2020-05-13 2023-07-04 ディスク・メディシン・インコーポレイテッド 骨髄線維症を処置するための抗ヘモジュベリン（ｈｊｖ）抗体

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20160332993A1 (en) * 2014-01-31 2016-11-17 Dana-Farber Cancer Institute, Inc. Diaminopyrimidine benzenesulfone derivatives and uses thereof
US20170174713A1 (en) * 2015-12-17 2017-06-22 Gilead Sciences Drive Tank-binding kinase inhibitor compounds

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20160332993A1 (en) * 2014-01-31 2016-11-17 Dana-Farber Cancer Institute, Inc. Diaminopyrimidine benzenesulfone derivatives and uses thereof
US20170174713A1 (en) * 2015-12-17 2017-06-22 Gilead Sciences Drive Tank-binding kinase inhibitor compounds

Non-Patent Citations (3)

* Cited by examiner, † Cited by third party
Title
DATABASE PubChem 28 May 2009 (2009-05-28), Database accession no. 28408238 *
DATABASE PubChem 3 September 2007 (2007-09-03), Database accession no. 16722836 *
DATABASE PubChem 30 November 2012 (2012-11-30), Database accession no. 67518325 *

Also Published As

Publication number Publication date
WO2018096525A2 (fr) 2018-05-31

Similar Documents

Publication Publication Date Title
WO2020084305A9 (fr) Ligands peptidiques bicycliques et leurs utilisations
WO2018006074A3 (fr) Composés et méthodes permettant de moduler la fonction de l'arn
EP3923935A4 (fr) Composés, compositions et procédés
MX2020007797A (es) Inhibidores de la cinasa 2 de control general no desrepresible (gcn2) y usos de los mismos.
WO2018109174A3 (fr) Anticorps anti-il-11
WO2017136450A3 (fr) Composés et méthodes de traitement de maladies médiées par l'arn
WO2017214170A3 (fr) Anticorps baff-r et utilisations de ceux-ci
WO2018025089A3 (fr) Compositions pharmaceutiques
WO2016205531A3 (fr) Anticorps anti-her2 et leurs procédés d'utilisation
EP4302827A3 (fr) Analogues de la rapamycine et leurs utilisations
EP3880194A4 (fr) Composés deutérés, compositions et utilisations
EP4112611A3 (fr) Modulateurs d'interaction sestrine-gator2 et leurs utilisations
WO2019229536A3 (fr) Nouveaux dérivés de benzodiazépine et leurs utilisations
WO2020123816A3 (fr) Anellosomes et méthodes d'utilisation
WO2017011340A3 (fr) Protéines et compositions immunisantes contenant des protéines de klebsiella et leurs procédés d'utilisation
EP3806906A4 (fr) Nouveaux composés cétogènes, compositions, procédés et utilisation de ceux-ci
ZA202103516B (en) Antibiotic compounds, methods of manufacturing the same, pharmaceutical compositions containing the same and uses thereof
WO2018096525A3 (fr) Composés hétéroaryle et utilisations associées
WO2018166993A3 (fr) Composés de pyrazolochlorophényle, compositions et méthodes d'utilisation associées
EP4319823A4 (fr) Composés de porphyrine-hydroporphyrine, compositions les comprenant et leurs procédés d'utilisation
WO2018211323A8 (fr) Composés hétérocycliques pour traiter une maladie
WO2018211324A8 (fr) Promédicaments pour traiter une maladie
CA3156248A1 (fr) Conjugues anticorps anti-cd37-maytansine et methodes d'utilisation de ceux-ci
WO2020139971A3 (fr) Procédés de fabrication de naphtalimides dimères et formes à l'état solide de ceux-ci
EP3864105A4 (fr) Compositions comprenant du 2,3,3,3-tétrafluoropropène

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 18726022

Country of ref document: EP

Kind code of ref document: A2

NENP Non-entry into the national phase

Ref country code: DE

ENP Entry into the national phase

Ref document number: 2018726022

Country of ref document: EP

Effective date: 20201027

122 Ep: pct application non-entry in european phase

Ref document number: 18726022

Country of ref document: EP

Kind code of ref document: A2